Real-world utilization and acceptance of tacrolimus-based immunosuppression in solid organ transplant recipients in India

Lav Patel, Shreekant Sharma, Deepak Bunger


Background: The objectives of the study were to describe the demographics and utilization pattern of tacrolimus (TAC)-based immunosuppressive regimens in recipients with solid organ transplant in India.

Methods: This real-world, multicenter (134 centers), retrospective analysis included data of solid organ transplant recipients between 2010 and 2022 who had received TAC-based immunosuppressive therapy. The study data was collected between April 2021 and March 2022.

Results: Data of a total of 1022 recipients with kidney transplant (KT, n=899) or liver transplant (LT, n=123) who received TAC-based immunosuppression was analyzed. The mean age of recipients among KT and LT was 41.04±10.62 and 42.88±11.32 years, respectively. The most common diseases leading to end stage organ failure were diabetes (24.7%), hypertension (15.8%), concomitant diabetes and hypertension (14.9%), chronic kidney disease (9.2%), nephrotic syndrome (5%), and end stage renal disease (ESRD, 4.4%) in KT recipients, whereas for LT, the common indications were liver cirrhosis (32.5%), hepatitis B viral infection (11.4%), alcoholic liver disease (10.6%), fatty liver disease (12, 9.8%) and non-alcoholic steatohepatitis (NASH, 5.7%). The source of transplant was living donor in majority of both KT (91.2%) and LT (77.2%) recipients. The most common induction regimen in KT was anti-thymocyte globulin (ATG), TAC, mycophenolate mofetil (MMF), and steroid (ATG+TAC+MMF+steroid, 42.3%) whereas in LT, it was TAC+MMF+steroid (67.5%); TAC+MMF+steroid was most common maintenance regimen (KT: 91.1%, LT: 78%).

Conclusions: Tacrolimus-based immunosuppression is widely used in the recipients of solid organ transplantation, including KT or LT in real‑world clinical practice in India.


Tacrolimus, Immunosuppression, Transplant, KT, LT

Full Text:



Ramesh V, Pal C. Organ Donation and Transplantation in India in 2019. Exp Clini Transplantation. 2021;19:1313-21.

Grinyó JM. Why is organ transplantation clinically important? Cold Spring Harbor perspectives Med. 2013;3.

Health Resources and Service Administration, USA. Organ Donation Statistics. Available at: Accessed on 25 September, 2022.

Enderby C, Keller CA. An overview of immunosuppression in solid organ transplantation. Am J Managed car. 2015;21:s12-23.

Prograf (tacrolimus). Northbrook, IL: Astellas Pharma US. 2013.

Mathew P, Mandal J, Patel K, Soni K, Tangudu G, Patel R et al. Bioequivalence of two tacrolimus formulations under fasting conditions in healthy male subjects. Clin Therap. 2011;33:1105-19.

Shroff S. Current trends in kidney transplantation in India. Ind J Urol. 2016;32:173-4.

Directorate General of Health Services. National Organ Transplant Programme. Available at: Accessed on 25 September, 2022.

Narasimhan G, Kota V, Rela M. Liver transplantation in India. Liver Transplantation. 2016;22:1019-24.

Jha VK, Mahapatra D, Jairam A, Singh V. Demographic Characteristics, Outcome and Complications of Renal Transplantations at a Tertiary Care Center in South India. J Asso Physicians Ind. 2021;69:28-31.

Kelly D, Sibal A. Current status of liver transplantation. Ind J Pediatr. 2003;70:731-6.

Finotti M, Auricchio P, Vitale A, Gringeri E, Cillo U. Liver transplantation for rare liver diseases and rare indications for liver transplant. Translational Gastroenterol Hepatol. 2021;6:27.

Adam R, Karam V, Cailliez V, JG OG, Mirza D, Cherqui D et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. Transplant Int. 2018;31:1293-317.

Hellemans R, Bosmans JL, Abramowicz D. Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies? Am J Transplantation. 2017;17:22-7.

Adam R, Karam V, Delvart V, Trunečka P, Samuel D, Bechstein WO et al. Improved Survival in Liver Transplant Recipients Receiving Prolonged-Release Tacrolimus in the European Liver Transplant Registry. Am J Transplantation. 2015;15:1267-82.

Wiseman AC. Induction Therapy in Renal Transplantation: Why? What Agent? What Dose? We May Never Know. Clin J Am Society Nephrol. 2015;10:923-5.